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Abstract 
Hypoxia, a hallmark of most solid tumours, is a negative prognostic factor due to its 
association with an aggressive tumour phenotype and therapeutic resistance. Given its 
prominent role in oncology, accurate detection of hypoxia is important, as it impacts on 
prognosis and could influence treatment planning. A variety of approaches have been 
explored over the years for detecting and monitoring changes in hypoxia in tumours, 
including biological markers and non–invasive imaging techniques. Positron emission 
tomography (PET) is the preferred method for imaging tumour hypoxia due to its high 
specificity and sensitivity to probe physiological processes in vivo, as well as the ability to 
provide information about intracellular oxygenation levels. This review provides an overview 
of imaging hypoxia with PET, with an emphasis on the advantages and limitations of the 
currently available hypoxia radiotracers. 
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Introduction 
Low oxygen concentration (hypoxia) is associated with many human pathological processes 
including ischemic heart disease, stroke and cancer. In oncology, hypoxic tumours are 
associated with a poor prognosis, an aggressive phenotype, increased risk of invasion and 
metastasis, and resistance to chemo and radiation therapy. A practical, robust and 
reproducible method of detecting and quantifying hypoxia could improve patient outcomes 
by allowing selection of more appropriate therapies to overcome the effects of hypoxia or 
allowing stratification of patients for more accurate prognostic information.  
 
Tumour hypoxia has been studied with various techniques: oxygen electrodes; extrinsic (e.g. 
pimonidazole) and intrinsic (e.g. carbonic anhydrase IX, CAIX) biomarkers; blood oxygen 
level–dependent (BOLD) and tissue oxygen level–dependent (TOLD) magnetic resonance 
imaging (MRI); single photon emission computed tomography (SPECT) and positron 
emission tomography (PET). Each technique interrogates different aspects of the hypoxic 
microenvironment, as they provide information on hypoxia at different locations: PET, 
SPECT and extrinsic markers, report on intracellular hypoxia (although not specifically 
inside cell nuclei and PET/SPECT images quantify data on a macroscopic scale in tumour 
regions), BOLD–MRI allows assessment of blood oxygenation using deoxy-haemoglobin as 
an endogenous marker, while oxygen electrodes, OxyLite sampling and electron 
paramagnetic resonance (EPR) predominantly measure interstitial hypoxia. Indirect methods 
that report on hypoxia–induced molecular events (e.g. GLUT1, CAIX expression) rather than 
hypoxia itself have also been employed as markers of tumour oxygenation. PET displays 
some advantages for studying hypoxia, as it can employ radiotracer probes that directly report 
on oxygen levels, in principle permitting the non-invasive and three–dimensional assessment 
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of intratumour  oxygen levels in a more direct manner, and not via hypoxia–mediated 
changes in phenotype. 
Due to the clinical significance of hypoxia imaging, an increasing number of hypoxia PET 
tracers are being evaluated in the clinic. This review provides a summary and discussion of 
tumour hypoxia imaging with PET, emphasising the attributes and limitations of the currently 
available hypoxia radiotracers. 
 
The significance of tumour hypoxia 
Tissue hypoxia is the result of inadequate tissue oxygenation due to an imbalance between 
oxygen supply and consumption. Hypoxia in solid tumours is largely due to the decreased 
delivery of oxygenated blood to meet the increased metabolic demands of the rapidly 
proliferating tumour cells. Other pathogenetic factors pre–eminent in the aetiology of tumour 
hypoxia lie in the chaotic and primitive tumour microvasculature which exhibits severe 
structural and functional abnormalities, heterogeneous microcirculation patterns, and an 
adverse geometry which poses limitations to oxygen diffusion. In addition, the reduced 
oxygen binding ability and/or transport capacity of haemoglobin, due to rouleaux formation, 
and the presence of disease– or therapy–related anaemia may also exacerbate hypoxia 
(Vaupel and Harison, 2004). 
 
Tumour hypoxia may be broadly classified as chronic and acute. Chronic or diffusion–limited 
hypoxia primarily arises as a consequence of the disorganised vascular architecture of 
tumours, where the distances between tumour microvessels are often increased from normal. 
Consequently, the diffusion distances of oxygen in perivascular space – typically 70–180 µm 
from the nearest capillary – are often exceeded. In addition, an adverse vascular geometry 
and prolonged reductions in blood oxygen content due to anaemia can also result in chronic 
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hypoxia. By contrast, acute or perfusion–limited hypoxia is characterised by fluctuations in 
tumour blood flow that are caused by transient reductions in perfusion. Both chronic and 
acute hypoxia can concur in tumours, leading to the formation of a highly dynamic 
microenvironment, where cells are exposed to differential oxygen gradients both spatially and 
temporally (Vaupel and Harrison, 2004). Owing to the dynamic and heterogeneous character 
of tumour hypoxia, imaging with PET presents an attractive alternative, as it does not require 
invasive biopsies, provides information across the entire tumour, and allows repeated and 
quantifiable measurements.  
 
Hypoxia has been shown to change gene expression to favour survival in a hostile 
environment (Bristow and Hill, 2008). The cellular response to hypoxia is mainly controlled 
by the family of hypoxia–inducible factors (HIFs), and may involve regulation of up to 1·5% 
of the human genome. HIF–1 – the best characterised member of the HIF family – is a 
heterodimeric protein, consisting of an oxygen responsive α–subunit and a constitutively 
expressed β–subunit. In the presence of oxygen, HIF–1α is continuously synthesised and 
degraded, but in hypoxic conditions, the protein accumulates, heterodimerises and acts as a 
transcription factor to up regulate a multitude of genes, including those involved in glucose 
metabolism, pH regulation, apoptosis, cell survival under oxidative stress, angiogenesis and 
erythropoiesis (Semenza, 2004). These characteristics eventually confer tumours with 
resistance to chemoradiation therapy and higher degrees of invasiveness. Furthermore, 
hypoxia itself reduces free radical formation induced by radiation, providing a physical 
contribution to resistance. Several retrospective immunohistochemical studies have 
demonstrated that hypoxia–mediated expression of HIF–1α and its downstream genes (e.g. 
glucose transporter 1, GLUT–1; vascular endothelial factor, VEGF; CAIX) is a negative 
prognostic indicator for many cancer types (Jubb et al, 2010). Treatment resistance to radio 
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and chemotherapy has also been demonstrated. Radiotherapy relies on the formation of free 
radicals which cause DNA damage; a mechanism that is enhanced in the presence of oxygen. 
Chemotherapeutic resistance may also be explained by a multitude of mechanisms, including 
extracellular acidification, resistance to apoptosis and increased genomic instability. 
Consequently, patients with hypoxic tumours often have a poor prognosis and decreased 
overall survival rate. 
 
Measuring tumour hypoxia with PET 
Radionuclide detection of hypoxia in tumours was first reported in 1981 with 
14
C–
misonidazole autoradiography (Chapman, 1979). Subsequently, two main tracer classes have 
been developed to specifically study hypoxia with PET: 
18
F–labelled nitroimidazoles and Cu–
labelled diacetyl–bis(N4–methylthiosemicarbazone) analogues (Figure 1).  
 
From a PET imaging perspective, hypoxia markers need to exhibit a number of different 
properties. The tracer must readily and non–specifically enter cells, sample the intracellular 
milieu, and leave cells only in the presence of relevant oxygen concentrations. A summary of 
the attributes of the ideal hypoxia tracer is presented in Table 1. Most PET tracers tested 
clinically broadly display attributes 1, 4, 5 and 7. The clinical utility of each tracer depends 
on these key properties, which will influence its distribution in tissues, clearance rate from 
blood, normoxic and hypoxic cells, metabolism, optimal image acquisition time and ease of 
synthesis, distribution. 
 
Nitroimidazole analogues 
2–nitroimidazole compounds were originally developed as hypoxic cell radiosensitisers and 
were introduced as hypoxia markers in the 1970’s (Chapman et al, 1979). Nitroimidazoles 
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enter cells by passive diffusion, where they undergo reduction forming a reactive 
intermediate species. Under normoxic conditions, these molecules are re–oxidised into their 
parent compound and diffuse out of the cell. However hypoxia causes further reduction of the 
nitro–radical anion, which eventually becomes irreversibly trapped in the cell at rates that are 
inversely proportional to the local pO2. As reduction of nitroimidazoles requires the presence 
of active tissue reductases, these compounds accumulate within viable hypoxic cells, but not 
apoptotic or necrotic cells.  
 
18
F–FMISO: Over the years, several fluorinated nitroimidazole–based markers have been 
developed for PET imaging. Of these, 
18
F
–
fluoromisonidazole (
18
F–FMISO) constitutes the 
prototype 2–nitroimidazole tracer, and is the most extensively clinically studied PET hypoxia 
biomarker. The lipophilic nature of this compound ensures facile cell–membrane penetration 
and diffusion into tissue, and several studies correlating direct oxygen measurements with 
18
F–FMISO accumulation in vivo demonstrate that a median oxygen level of ≤10 mmHg is 
generally required for hypoxia–specific retention. 18F–FMISO accumulation has been found 
to reflect hypoxia in gliomas (Valk et al, l992; Bruehlmeier et al, 2004; Rajendran et al, 
2004; Cher et al 2006; Swanson et al 2009), head–and–neck (Rasey et al, 1996; Gagel et al, 
2004, 2007; Hicks et al, 2005; Thorwarth et al, 2006; Zimny et al, 2006; Mortensen et al, 
2010; Abolmaali et al, 2011; Sato et al, 2013), breast (Cheng et al, 2013), lung (Cherk et al, 
2006; Vera et al, 2011) and renal tumours (Hugonet et al, 2011). However, 
18
F–FMISO 
retention in sarcomas is variable (Rajendran et al, 2003; Mortensen et al, 2010), rectal 
18
F–
FMISO imaging is compromised by high non–specific tracer accumulation in normoxic 
tissue (Roels et al, 2008) whereas no retention was observed in pancreatic tumours (Segard et 
al, 2013). Several clinical studies have shown that a tumour–to–blood activity ratio ≥ 1.2 
imaged after at least two hours post injection (p.i.) can be generally considered as indicative 
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of hypoxia (Table 2). Although not commercially available, 
18
F–FMISO is produced by a 
number of institutions, making it available for research purposes. 
Due to its hypoxic selectivity, 
18
F–FMISO is the lead candidate in the assessment of hypoxia 
with PET. However, despite its wide applicability, 
18
F–FMISO has not gained general 
acceptance for routine clinical use due to its slow pharmacokinetic profile: the limited 
clearance of the tracer from normal tissue and blood results in modest hypoxic–to–normoxic 
tissue ratios (Fig 2) and therefore images with moderate contrast (Fig 3a). The limited 
hypoxic contrast may potentially impede visual detection of hypoxic regions, and has 
hampered diagnostic utility in routine practice. Therefore, considerable efforts have been 
made to develop hypoxia markers with improved pharmacokinetic properties (enhanced 
clearance of the tracer from normoxic tissues) that are more amenable to clinical use. These 
are discussed below.  
 
18
F–FAZA: 18F–fluoroazomycin–arabinofuranoside (18F–FAZA) is more hydrophilic than 
18
F–FMISO. Consequently, there are faster clearance kinetics, resulting in improved tumour–
to–reference tissue ratios, and thus hypoxia–to–normoxia contrast. 18F–FAZA imaging has 
been successful in gliomas (Postema et al, 2009), lymphomas (Postema et al, 2009), lung 
(Postema et al, 2009; Bollineni et al, 2013; Trinkaus et al, 2013), head–and–neck (Postema et 
al, 2009; Souvatzoglou et al, 2007; Grosu et al, 2007; Mortensen et al 2012), cervical 
(Schuetz et al, 2010) and rectal tumours (Havelund et al, 2013), and results have been shown 
to compare favourably with equivalent 
18
F–FMISO data, especially as improved hypoxic–
normoxic contrast was obtained at earlier time–points. No 18F–FAZA accumulation has been 
observed in prostate tumours, although hypoxia may not be a characteristic of this particular 
tumour type, as in the same study, CAIX immunohistochemistry was also found to be 
negative in these lesions (Garcia-Parra et al, 2011). High 
18
F–FAZA tumour–to–reference 
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tissue values have been associated with reduced disease–free survival and have shown 
prognostic potential in the detection of hypoxia in head–and–neck patients (Mortensen et al, 
2012). Due to the higher tumour–to–reference tissue ratios in comparison to 18F–FMISO, 
18
F–FAZA is gaining popularity for PET imaging of tumour hypoxia. Despite the fact that 
18
F–FAZA is not widely available at present, increasing research demand may persuade more 
sites to produce it.  
 
18
F–FETNIM: 18F–fluoroerythronitroimidazole (18F–FETNIM) studies in head–and–neck 
(Lehtiö et al, 2001, 2003), lung (Li et al, 2010; Hu et al, 2013) and oesophageal cancer Yue 
et al, 2012 calculated T:M in the range of 1.4–2.48 at two hours p.i. High tumour–to–muscle 
values were found to be indicative of reduced progression–free and overall survival in lung 
(Hu et al, 2013), head–and–neck (Lehtiö et al, 2001) oesophageal (Yue et al, 2012), and 
cervical (Vercellino et al 2012). Clinical studies with 
18
F–FETNIM have been mainly carried 
out at the University of Turku, Finland. 
18
F–FETNIM is not being used at present in the UK 
or the USA.  
 
18
F–RP–170: More recently, RP–170 (1–(2–1–(1H–methyl)ethoxy)methyl–2–
nitroimidazole), another 2–nitroimidazole–based hypoxic radiosensitiser, has also been 
labelled with 
18
F. The hypoxic selectivity of 
18
F–FRP–170 was demonstrated in glioma 
patients on the basis of significant correlations between uptake, oxygen tension 
measurements and HIF–1α immunostaining (Beppu et al, 2014). Studies in brain (Shibahara 
et al, 2010; Beppu et al, 2014) and lung (Kaneta et al, 2007) tumours indicated higher SUV 
for hypoxic than normal tissues; tumour–to–reference tissue ratio of 1.7 were calculated at 
one hour p.i., which could be clinically sufficient for assessing hypoxia. The shorter interval 
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prior to scanning, combined with improved hypoxic contrast compared to 
18
F–FMISO, 
suggests that 
18
F–FRP–170 could potentially be useful in the clinic.  
  
18
F–HX4: 18F–3–fluoro–2–(4–((2–nitro–1H–imidazol–1–yl)methyl)–1H–1,2,3–triazol–1–
yl)propan–1–ol (18F–HX4) contains  a 1,2,3–anti–triazole moiety (as a synthetic convenience) 
rendering it more hydrophilic than 
18
F–FMISO. In head–and–neck tumours 18F–HX4 
produced tumour–to–reference tissue values similar to 18F–FMISO at relatively early time 
points p.i., indicating the potential advantage of shorter acquisition times (Chen et al, 2012). 
However a more recent study in non–small–cell lung cancer (NSCLC) patients (Zegers et al, 
2013) suggested that later scan times (2–4 hrs p.i.) can further enhance the hypoxic–to–
normoxic signal. In all of the above tracers the more accurate hypoxic measure is made at 
least two hours post injection, but the trade–off is the reduced radioactivity and noisier data. 
 
Cu–ATSM 
An alternative class of agents for the study of hypoxia with PET is based on a complex of Cu 
with diacetyl–bis(N4–methylthiosemicarbazone) ligands, among which diacetyl–bis(N4–
methylthiosemicarbazone) (ATSM) is the prototype. Due to its lipophilicity and low 
molecular weight, Cu–ATSM is characterised by high membrane permeability and therefore 
rapid diffusion into cells. The hypoxic specificity of Cu–ATSM is thought to be partly 
imparted by the intra–cellular reduction of Cu(II) to Cu(I) combined with re–oxidation by 
intra–cellular molecular oxygen. Under hypoxic conditions, the unstable Cu(I)–ATSM 
complex may further dissociate into Cu(I) and ATSM, leading to the intra–cellular trapping 
of the Cu(I) ion. In the presence of oxygen, the [Cu(I)–ATSM]– can be re–oxidised to its 
parent compound, allowing efflux from the cell (Dearling and Packard, 2010) .  
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Tumour–specific Cu–ATSM retention has been demonstrated for head–and–neck (Minagawa 
et al, 2011; Nyflot et al, 2012) (Fig 3b), lung (Takahashi et al, 2000; Dehdashti et al, 2003; 
Lolith et al, 2009), cervical (Dehdashti et al, 2003; Grisby et al, 2007; Lewis et al, 2008; 
Dehdashti et al, 2008), rectal tumours (Dietz et al, 2008) and gliomas (Tateishi et al, 2013). 
Hypoxia specificity may be dependent on tumour type: preclinical studies showed good 
correlation in the intra–tumour distribution of Cu–ATSM and 18F–FMISO in a FaDu 
squamous carcinoma model but not at early time points in an R3327–AT anaplastic rat 
prostate tumour (O'Donoghue et al, 2005). A recent study has raised concerns about the 
hypoxic specificity of Cu–ATSM, as hepatic metabolism of the compound results in images 
that reflect the behaviour of ionic Cu (uptake of which may itself be hypoxia–related) rather 
than Cu–ATSM itself, especially at later time points (1–24 hrs) (Hueting et al, 2014). Of 
concern is also the fact that while some preclinical studies show that tumour uptake of 
hypoxia–selective Cu–ATSM analogues (e.g. Cu–ATSE) decreases with increased 
oxygenation (McQuade et al, 2005), another report showed that increased oxygenation 
resulted in a decrease in uptake of FMISO, but not of Cu–ATSM (Matsumoto et al, 2007). 
Nevertheless, 
64
Cu–ATSM retention has been shown to correlate clinically with poor 
prognosis (Dehdashti et al, 2003, 2008; Grisby et al, 2007; Dietz et al 2008). Attempts to 
investigate the relationship between the intra–tumoural distribution of Cu–ATSM with 
histological and other hypoxia markers have also yielded both positive and negative 
correlations. Although it appears to be premature to reject Cu–ATSM on the grounds of 
hypoxic non–specificity, further studies are required to elucidate the in vivo behaviour of this 
tracer to allow for better interpretation of the imaging information. The development of 
second generation Cu–ATSM analogues, with reduced lipophilicity and improved hypoxia 
selectivity and sensitivity, appear a promising alternative to Cu–ATSM (Handley et al, 2014). 
Cu–ATSM has several potential advantages relative to other tracers for the imaging of 
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tumour hypoxia, including simpler synthesis/radiolabelling methodology and faster clearance 
from normoxic tissues, which allows shorter intervals between injection and imaging and 
higher hypoxic–to–normoxic contrast. Notwithstanding the limited availability of Cu 
isotopes, 
64
Cu–ATSM is currently being produced at a few research sites, and due to the 12 
hour half–life could potentially be utilised for clinical studies.  
Clinical applications of PET hypoxia imaging 
Identification of tumour hypoxia and prediction of prognosis/response to treatment 
Identifying individuals with poor prognosis and those likely to benefit from hypoxia–targeted 
therapy are important objectives of PET hypoxia research. Several studies have shown that 
PET hypoxia imaging can provide information on prognosis. High 
18
F–FMISO retention has 
been associated with higher risk of loco–regional failure and shorter progression–free 
survival in head–and–neck (Rischin et al, 2006; Rajendran et al, 2006; Thorwarth et al, 2006; 
Dirix et al, 2009; Lee et al, 2009; Kikuchi et al, 2011)
 
 and renal cancer (Hugonet et al, 
2011). Furthermore, a meta–review of the clinical data of over 300 patients concluded that 
FMISO is a predictor of poor treatment response and prognosis (Lee and Scott, 2007). 
Similar results have been reported for 
18
F–FETNIM in lung (Li et al, 2010), head–and–neck 
(Lehtiö et al, 2004), and oesophageal cancer (Yue et al, 2012), where high tumour–to–
reference tissue values were also associated with poor patient outcomes. Studies conducted 
with 
18
F–FAZA in squamous cell carcinomas of the head and the neck (Mortensen et al, 
2012) and Cu–ATSM in patients with cervical (Dehdashti et al, 2003; Grigsby et al, 2007), 
lung (Dehdashti et al, 2003) and rectal cancer (Dietz et al, 2008) have also demonstrated that 
lower tumour–to–muscle ratios are indicative of better prognosis, progression–free and 
overall survival. A meta–analysis of published PET hypoxia studies has demonstrated a 
common tendency towards poorer outcome in tumours showing higher tracer accumulation 
(Horsman et al, 2012). Decreased 
18
F–FMISO uptake in response to radio– or chemotherapy 
14 
 
has been reported in brain (Swanson et al, 2009), head–and–neck (Yamane et al, 2011; 
Eschmann et al, 2007), lung (Koh et al, 1995; Gagel et al, 2006), and renal tumours (Hugonet 
et al, 2011); although some studies did not observe an analogous decrease with response to 
therapy (Thorwarth et al, 2006; Vera et al, 2011). Decreased tumour–to–muscle ratios 
signifying full or partial response to chemotherapy have also been obtained with Cu–ATSM 
in lung (Dehdashti et al, 2003) and head–and–neck tumours (Minagawa et al, 2011), and 18F–
FAZA in lung cancer (Trinkaus et al, 2013).  
 
Radiotherapy planning 
In oncology, there is interest in the identification of intra–tumoural areas with hypoxia to 
guide radiation dose escalation to radio–resistant sub–volumes. Despite possible limitations 
associated with the reproducibility of hypoxic volume measurements (temporal changes 
and/or heterogeneity in the spatial distribution of intra–tumoural hypoxia), the biological 
information from PET hypoxia scans is being explored for the identification and delineation 
of hypoxic areas within the tumour mass for dose escalation. Modern radiation techniques, 
such as intensity modulated radiotherapy (IMRT) or image–guided radiotherapy (IGRT) can 
help with radiotherapy planning (Horsmann et al, 2012). “Dose painting” by numbers, where 
a higher radiation dose is selectively delivered to areas of biological resistance identified 
either before or during the treatment course, has also been suggested (Geets et al, 2013). The 
feasibility of dose escalation to hypoxic sub–volumes has been primarily investigated in 
cancers of the head and neck, lung, and brain, and demonstrated with Cu–ATSM (Chao et al, 
2001), 
18
F–FMISO (Lee et al, 2008), and 18F–FAZA (Grosu et al, 2007). Despite the fact that 
the majority of the aforementioned studies have not been conducted on actual patients, but on 
anthropomorphic phantoms (in silico) (Richin et al, 2006; Grosu et al, 2007; Lee et al, 2008) 
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, dose escalation on the basis of PET hypoxia imaging appears feasible, and further studies 
are required to investigate whether this can translate into clinical benefit. 
 
Hypoxia therapeutics 
As the hypoxic microenvironment constitutes a unique characteristic of tumours, hypoxia can 
also be harnessed as a therapeutic target. The main strategies for targeting hypoxia involve 
hypoxic cell radiosensitisers (e.g. nimorazole), hypoxic cell cytotoxins (e.g. tirapazamine, 
TH–302, PR–104A); and altering oxygen delivery (e.g. carbogen plus nicotinamide). Other 
approaches being investigated include hypoxia–selective gene therapy, altering metabolic 
pathways essential for survival under stress, and inhibitors of molecular targets activated in 
hypoxia (e.g. HIF–1) (Wilson and Hay, 2011). Imaging hypoxia with PET could facilitate the 
development of therapeutic agents by identifying patients with hypoxic tumours, and 
measuring response to hypoxia–modifying treatments providing a basis for individualising 
hypoxia–specific treatment, and/or assessing drug efficacy. Furthermore, it will allow 
development of new predictors and answer key questions, such as the relation of baseline or 
induced hypoxia to response to anti–angiogenic drugs and the relation of baseline hypoxia to 
response to hypoxic activated toxins. Such studies should be incorporated into trials of these 
agents routinely, to develop the necessary validation for their utility. This would greatly help 
the personalised and economic use of such therapies, which will be even more important if 
used in combination, e.g. anti–angiogenics and hypoxia–activated toxins. The potential of 
PET hypoxia imaging in directing hypoxia therapeutics has been clinically demonstrated with 
tirapazamine with 
18
F–FMISO in head and neck tumours, whereby only those with hypoxia 
benefited from bioreductive drugs (Richin et al, 2006; Overgaard et al, 2011).  
 
Considerations 
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1. The “ideal” PET tracer for tumour hypoxia 
Table 3 presents a summary of clinical imaging findings with the hypoxia tracers discussed in 
this review. None of the currently available tracers have all the properties that constitute the 
ideal PET hypoxia tracer, and therefore none is optimal for imaging hypoxia in all cancer 
types. Nevertheless, the feasibility of imaging hypoxia with PET has been clinically 
demonstrated in various tumour entities using several of the existing radiotracers. Much of 
the radiotracer selection stems from the availability of the tracer, ease of synthesis and the 
tumour type. 
 
2. The magnitude of the challenge of PET hypoxia imaging 
A challenging aspect of PET hypoxia imaging is the fact that hypoxic tumours are often 
hypoperfused. Limited perfusion will restrict effective delivery of tracer into the tissue often, 
influencing tracer accumulation in regions of normal or tumour tissue, and often yielding 
results that are complex to interpret. Several studies have compared tumour perfusion with 
dynamic PET to ascertain whether tracer accumulation reflects blood flow during imaging. 
18
F–FMISO (Bruehlmeier et al, 2004), 18F–FETNIM (Lehtiö et al, 2001) and 18F–FAZA (Shi 
et al, 2010) exhibited similar distribution patterns to [
15
O]–H2O PET (reflecting blood flow) 
up to 15 min p.i., while different patterns were observed at later imaging times, consistent 
with tracer accumulation in hypoxic regions. Pharmacokinetic analysis of 
18
F–FMISO data 
suggests that different hypoxia–perfusion profiles can be identified in tumours (Thorwarth et 
al, 2005); the latter perhaps corresponding with the heterogeneity observed in tumour 
hypoxia distribution patterns (Grosu et al, 2007). The significant heterogeneity of the tumour 
microenvironment in terms of perfusion and hypoxia necessitates further clinical studies, not 
only to evaluate hypoxia–perfusion patterns, but also their relationship to clinical outcome. 
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3. Validation of PET hypoxia measurements 
Validation of PET tracers as indicators of regional hypoxia is extremely challenging and 
attempts to correlate PET images with other accepted hypoxia markers have produced mixed 
and contradictory results. While oxygen electrodes are considered to be the gold standard 
against which PET hypoxia measurements are authenticated, comparisons may yield several 
discrepancies due to the sampling limitations of oxygen probes and the fact that it measures 
hypoxia in a different location (interstitial for oxygen probes vs. intracellular for PET), as 
well as the fact that this technique will fail to distinguish between necrotic and viable hypoxic 
tissue (Höckel et al, 1993). This may partly explain results from several studies that have 
reported mixed correlations between tracer uptake and oxygen electrode measurements in 
various tumour types (Bentzen et al, 2003; Gagel et al, 2004, 2007; Zimny et al, 2006; 
Mortensen et al, 2010). Indirect immunohistochemical methods based on the detection of 
exogenous (e.g. pimonidazole, EF5) or endogenous hypoxia markers (e.g. CAIX, HIF–1) 
have also been employed (Dehdashti et al, 2003; Jubb et al, 2010), albeit with limited 
success. This is primarily due to the fact that comparisons as such rely on reproducible 
staining, and several representative biopsies (which are not always available), and may often 
require a technically challenging spatial co–registration between PET images with 
immunohistochemistry photographs for analogies to be drawn. Of note is the fact that 
although tracer accumulation has been widely compared with pimonidazole staining 
preclinically (Dubois et al, 2004), equivalent clinical comparisons have not yet been 
performed. The differential detection of acute and chronic hypoxia and the discrepancy 
between hypoxia at the microscopic level and the macroscopic resolution of the PET voxel 
are factors that will also limit the accuracy of such comparisons (Mortensen et al, 2010)  
 
4. Reproducibility of PET hypoxia measurements 
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Validation of the reproducibility of PET hypoxia measurements is also particularly important 
for clinical applications. There are limited clinical data available on scan reproducibility with 
PET hypoxia biomarkers. Studies with 
18
F–FMISO in head–and–neck cancer reported 
reproducible hypoxic volumes in PET scans performed three days apart, but a considerable 
degree of intra–tumoural spatial variability in tracer accumulation (Nehmeh et al, 2008). 
Another study with 
18
F–FMISO in lung cancer showed good inter-observer reproducibility on 
the basis of visual analysis, but low inter–observer agreement with respect to hypoxic volume 
measurements (Thureau et al, 2013). A more recent 
18
F–FMISO study in head–and–neck 
cancer reported high reproducibility in SUV and tumour–to–reference tissue measurements in 
scans acquired two days apart (Okamoto et al, 2013). Other than 
18
F–FMISO, a study with 
18
F–FETNIM in oesophageal cancer patients observed similar uptake values between scans 
performed on separate days before concurrent chemoradioatherapy, but a shift in the 
geographical location of hypoxic regions (Yue et al, 2012). These heterogeneous findings can 
be partly explained by the dynamic character of hypoxia that will limit scan reproducibility. 
Although acute hypoxia has been shown to minimally influence 
18
F–FMISO PET imaging in 
simulations (Mönnich et al, 2012), a study in head–and–neck tumours that used sequential 
18
F–FMISO scans to distinguish between regions of acute and chronic hypoxia, accounted for 
14–52% of acute hypoxia (Wang et al, 2009); a percentage that is comparable to the 
proportion of acute hypoxia measured in rodent tumours. Methodological discrepancies (scan 
setup, image acquisition protocol), the selection of hypoxic–to–normoxic thresholds for the 
definition of hypoxic regions, the temporal variability in intra–tumoural pO2 levels between 
consecutive measurements, as well as the small number of patients in the majority of the 
studies may also account for the observed disparities in reproducibility. Further studies 
addressing the variability of PET hypoxia measurements are warranted, so as to clarify 
uncertainties in tumour hypoxia quantification. 
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Conclusions 
As a number of PET hypoxia tracers have now been evaluated in cancer patients, it is 
apparent that PET imaging can be a powerful tool to identify hypoxia in the clinical setting. 
Although none of the currently available tracers exhibit all of the properties of the ‘ideal’ 
hypoxia tracer or are optimal for imaging hypoxia in all tumour types, studies have 
demonstrated the feasibility for imaging hypoxia in various cancers. As the clinical utility and 
limitations of PET hypoxia biomarkers are now being elucidated the process will be 
facilitated by performing larger studies with these tracers using standardised protocols and 
hypoxia definitions so as to improve comparison between tracers in various tumour types. 
This may be best achieved via inter-institutional collaborations which should help to advance study 
designs and homogeneous data reporting. Equally important are the performance of test–retest 
studies, harmonisation of data reporting, and clinical validation of hypoxia tracers. These key 
objectives must be addressed before PET hypoxia tracers can be used to their full clinical 
utility. 
 
Search strategy and selection criteria 
We searched PubMed and Scopus using combinations of the following search terms: “tumor 
hypoxia”, “oncology”, “PET”, “positron emission tomography”, radiotherapy”, 
“nitroimidazoles”, “fluoromisonidazole”, “pimonidazole”, “FMISO”, “FAZA”, “FETNIM”, 
“FRP–170”, “HX4”, “Cu–ATSM”. The search results were screened for relevance and the 
reference lists of relevant publications were also surveyed. PubMed and Scopus article 
recommendations were also examined for relevance. Only papers published in English were 
considered. The final reference list was compiled by considering papers published between 
January 1973 and May 2014.  
20 
 
 
Conflicts of interest 
The authors declare that they have no conflicts of interest. 
 
Acknowledgements 
Cancer Research UK (CRUK) funded the National Cancer Research Institute (NCRI) PET 
Research Working party to organise a meeting to discuss imaging cancer with hypoxia tracers 
and Positron Emission Tomography. IF was funded by CRUK and is also supported by the 
Chief Scientific Office. ALH is supported by CRUK and the Breast Cancer Research 
Foundation. RM is funded by NIHR Cambridge Biomedical Research Centre. The authors 
would also like to thank Professors Tim Eisen and Duncan Jodrell, University of Cambridge, 
UK and Dr Anastasia Chalkidou, King’s College London, UK for providing the 18F–FMISO 
and 
64
Cu–ATSM images illustrated in this review.  
 
References  
Abolmaali N, Haase R, Koch A, Zips D, Steinbach J, Baumann M, Kotzerke J, Zöphel K 
(2011) Two or four hour [
18
F]FMISO–PET in HNSCC: When is the contrast best? 
Nuklearmedizin 50(1): 22–7. 
Bentzen L, Keiding S, Nordsmark M, Falborg L, Hansen SB, Keller J, Nielsen OS, 
Overgaard J (2003) Tumour oxygenation assessed by 
18
F–fluoromisonidazole PET and 
polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 67(3): 339–
44. 
Beppu T, Terasaki K, Sasaki T, Fujiwara S, Matsuura H, Ogasawara K, Sera K, Yamada N, 
Uesugi N, Sugai T, Kudo K, Sasaki M, Ehara S, Iwata R, Takai Y (2014) Standardized 
21 
 
Uptake Value in High Uptake Area on Positron Emission Tomography with 
18
F–FRP170 as a 
Hypoxic Cell Tracer Correlates with Intratumoral Oxygen Pressure in Glioblastoma. Mol 
Imaging Biol 16(1): 1–9. 
Bollineni VR, Kerner GSMA, Pruim J, Steenbakkers RJ, Wiegman EM, Koole MJ, de Groot 
EH, Willemsen AT, Luurtsema G, Widder J, Groen HJ, Langendijk JA (2013) PET imaging 
of tumor hypoxia using 
18
F–fluoroazomycin arabinoside in stage III–IV non–small cell lung 
cancer patients. J Nucl Med 54(8): 1175–80. 
Bristow RG, Hill RP (2008) Hypoxia and metabolism: Hypoxia, DNA repair and genetic 
instability. Nat Rev Cancer 8(3): 180–92.  
Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM (2004) Assessment of hypoxia 
and perfusion in human brain tumors using PET with 
18
F–fluoromisonidazole and 15O–H2O. 
J Nucl Med; 45(11): 1851–9. 
Chao KSC, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez 
CA, Purdy JA, Welch MJ (2001) A novel approach to overcome hypoxic tumor resistance: 
Cu–ATSM–guided intensity–modulated radiation therapy. Int J Radiat Oncol Biol Phys 
49(4): 1171–82. 
Chapman JD (1979) Hypoxic sensitisers – Implications for radiation therapy. N Engl J Med 
301(26): 1429–32.  
Chen L, Zhang Z, Kolb HC, Walsh JC, Zhang J, Guan Y (2012) 
18
F–HX4 hypoxia imaging 
with PET/CT in head and neck cancer: A comparison with 
18
F–FMISO. Nucl Med Commun 
33(10): 1096–102. 
22 
 
Cheng J, Lei L, Xu J, Sun Y, Zhang Y, Wang X, Pan L, Shao Z, Zhang Y, Liu G (2013) 
18
F–
fluoromisonidazole PET/CT: A potential tool for predicting primary endocrine therapy 
resistance in breast cancer. J Nucl Med 54(3): 333–40. 
Cher LM, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A, O'Keefe GJ, 
Sachinidis JI, Berlangieri SU, Fabinyi G, Scott AM (2006) Correlation of hypoxic cell 
fraction and angiogenesis with glucose metabolic rate in gliomas using 
18
F–
fluoromisonidazole, 
18
F–FDG PET, and immunohistochemical studies. J Nucl Med 2006 
47(3): 410–8.  
Cherk MH, Foo SS, Poon AMT, Knight SR, Murone C, Papenfuss AT, Sachinidis JI, 
Saunder TH, O'Keefe GJ, Scott AM (2006) Lack of correlation of hypoxic cell fraction and 
angiogenesis with glucose metabolic rate in non–small cell lung cancer assessed by 18F– 
fluoromisonidazole and 
18
F–FDG PET. J Nucl Med 47(12): 1921–26. 
Dearling JLJ, Packard AB (2010) Some thoughts on the mechanism of cellular trapping of 
Cu(II)–ATSM. Nucl Med Biol 37(3): 237–43. 
Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ (2003) Assessing 
tumor hypoxia in cervical cancer by positron emission tomography with 
60
Cu–ATSM: 
Relationship to therapeutic response – A preliminary report. Int J Radiat Oncol Biol Phys 
55(5): 1233–8. 
Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, Welch MJ, Siegel 
BA (2003) In vivo assessment of tumor hypoxia in lung cancer with 
60
Cu–ATSM. Eur J Nucl 
Med Mol Imaging; 30(6): 844–50. 
23 
 
Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ (2008) Assessing 
tumor hypoxia in cervical cancer by PET with 
60
Cu–labeled diacetyl–bis(N4–
methylthiosemicarbazone). J Nucl Med 49(2): 201–5. 
Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, 
Welch MJ, Siegel BA (2008) Tumor hypoxia detected by positron emission tomography with 
60
Cu–ATSM as a predictor of response and survival in patients undergoing neoadjuvant 
chemoradiotherapy for rectal carcinoma: A pilot study. Dis Colon Rectum 51(11): 1641–8. 
Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S (2009) Dose 
painting in radiotherapy for head and neck squamous cell carcinoma: Value of repeated 
functional imaging with 
18
F–FDG PET, 18F–fluoromisonidazole PET, diffusion–weighted 
MRI, and dynamic contrast–enhanced MRI. J Nucl Med 50(7): 1020–7. 
Dubois L, Landuyt W, Haustermans K, Dupont P, Bormans G, Vermaelen P, Flamen P, 
Verbeken E, Mortelmans L (2004) Evaluation of hypoxia in an experimental rat tumour 
model by [ 
18
F]Fluoromisonidazole PET and immunohistochemistry. Br J Cancer 91(11): 
1947–54. 
Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M, Bares R (2007) 
Hypoxia–imaging with 18F–Misonidazole and PET: Changes of kinetics during radiotherapy 
of head–and–neck cancer. Radiother Oncol 83(3): 406–10. 
Gagel B, Reinartz P, DiMartino E, Zimny M, Pinkawa M, Maneschi P, Stanzel S, Hamacher 
K, Coenen HH, Westhofen M, Büll U, Eble MJ (2004) pO2 polarography versus positron 
emission tomography ([
18
F] fluoromisonidazole, [
18
F]–2–fluoro–2′– deoxyglucose): An 
appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 180(10): 616–22.  
24 
 
Gagel B, Reinartz P, Demirel C, Kaiser HJ, Zimny M, Piroth M, Pinkawa M, Stanzel S, 
Asadpour B, Hamacher K, Coenen HH, Buell U, Eble MJ (2006) [
18
F]–fluromisonidazole 
and [
18
F] fluorodeoxyglucose positron emission tomography in response evaluation after 
chemo–/radiotherapy of non–small–cell lung cancer: A feasibility study. BMC Cancer 6: 51. 
Gagel B, Piroth M, Pinkawa M, Reinartz P, Zimny M, Kaiser HJ, Stanzel S, Asadpour B, 
Demirel C, Hamacher K, Coenen HH, Scholbach T, Maneschi P, DiMartino E, Eble MJ 
(2007) pO polarography, contrast enhanced color duplex sonography (CDS), [
18
F] 
fluoromisonidazole and [
18
F] fluorodeoxyglucose positron emission tomography: Validated 
methods for the evaluation of therapy–relevant tumor oxygenation or only bricks in the 
puzzle of tumor hypoxia? BMC Cancer 7: 113. 
Garcia–Parra R, Wood D, Shah RB, Siddiqui J, Hussain H, Park H, Desmond T, Meyer C, 
Piert M (2011) Investigation on tumor hypoxia in resectable primary prostate cancer as 
demonstrated by 
18
F–FAZA PET/CT utilizing multimodality fusion techniques. Eur J Nucl 
Med Mol Imaging 2011; 1–8. 
Geets X, Grégoire V, Lee JA (2013) Implementation of hypoxia PET imaging in radiation 
therapy planning. Q J Nucl Med Mol Imaging 57(3): 271–82. 
Grigsby PW, Malyapa RS, Higashikubo R, Schwarz JK, Welch MJ, Huettner PC, Dehdashti 
F (2007) Comparison of molecular markers of hypoxia and imaging with 60Cu–ATSM in 
cancer of the uterine cervix. Mol Imaging Biol 9(5): 278–83. 
Grosu AL, Souvatzoglou M, Röper B, Dobritz M, Wiedenmann N, Jacob V, Wester HJ, 
Reischl G, Machulla HJ, Schwaiger M, Molls M, Piert M (2007) Hypoxia Imaging With 
FAZA–PET and Theoretical Considerations With Regard to Dose Painting for 
25 
 
Individualization of Radiotherapy in Patients With Head and Neck Cancer. Int J Radiat 
Oncol Biol Phys 69(2): 541–51. 
Handley MG, Medina RA, Mariotti E, Mariotti E, Kenny GD, Shaw KP, Yan R, Eykyn TR, 
Blower PJ, Southworth R. (2014) Cardiac hypoxia imaging: Second–generation analogues of 
64
Cu–ATSM. J Nucl Med 55(3): 488–94. 
Havelund BM, Holdgaard PC, Rafaelsen SR, Mortensen LS, Theil J, Bender D, Pløen J, 
Spindler KL, Jakobsen A (2013) Tumour hypoxia imaging with 
18
F–
fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer. 
Nucl Med Commun 34(2): 155–61. 
Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ (2005) Utility of FMISO PET 
in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia–
targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 32(12): 1384–91. 
Höckel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, Knapstein PG, 
Vaupel P (1993) Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. 
Radiother Oncol 26(1): 45–50. 
Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J (2012) Imaging hypoxia to 
improve radiotherapy outcome. Nat Rev Clin Oncol 9(12): 674–87. 
Hu M, Xing L, Mu D, Yang W, Yang G, Kong L, Yu J (2013) Hypoxia imaging with 
18
F–
fluoroerythronitroimidazole integrated PET/CT and immunohistochemical studies in non–
small cell lung cancer. Clin Nucl Med 38(8): 591–6. 
26 
 
Hueting R, Kersemans V, Cornelissen B, Tredwell M, Hussien K, Christlieb M, Gee AD, 
Passchier J, Smart SC, Dilworth JR, Gouverneur V, Muschel RJ (2014) A comparison of the 
behavior of 
64
Cu–acetate and 64Cu–ATSM in vitro and in vivo. J Nucl Med 55(1): 128–34. 
Hugonnet F, Fournier L, Medioni J, Smadja C, Hindié E, Huchet V, Itti E, Cuenod CA, 
Chatellier G, Oudard S, Faraggi M; Hypoxia in Renal Cancer Multicenter Group (2011) 
Metastatic renal cell carcinoma: Relationship between initial metastasis hypoxia, change after 
1 month's sunitinib, and therapeutic response: An 
18
F–fluoromisonidazole PET/CT study. J 
Nucl Med 52(7): 1048–55. 
Jubb AM, Buffa FM, Harris AL (2010) Assessment of tumour hypoxia for prediction of 
response to therapy and cancer prognosis. J Cell Mol Med 14(1–2): 18–29.  
Kaneta T, Takai Y, Iwata R, Hakamatsuka T, Yasuda H, Nakayama K, Ishikawa Y, Watanuki 
S, Furumoto S, Funaki Y, Nakata E, Jingu K, Tsujitani M, Ito M, Fukuda H, Takahashi S, 
Yamada S (2007) Initial evaluation of dynamic human imaging using
18
F–FRP170 as a new 
PET tracer for imaging hypoxia. Ann Nucl Med 21(2): 101–7.  
Kikuchi M, Yamane T, Shinohara S, Fujiwara K, Hori SY, Tona Y, Yamazaki H, Naito Y, 
Senda M (2011) 
18
F–fluoromisonidazole positron emission tomography before treatment is a 
predictor of radiotherapy outcome and survival prognosis in patients with head and neck 
squamous cell carcinoma. Ann Nucl Med 25(9): 625–33. 
Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, Grierson JR, 
Lindsley KL, Lewellen TK, Krohn KA, Griffin TW (1995) Evaluation of oxygenation status 
during fractionated radiotherapy in human nonsmall cell lung cancers using [F–
18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995; 
33(2): 391–8. 
27 
 
Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, Chan K, Zanzonico PB, Greco 
C, Ling CC, Humm JL, Schöder H (2008) Fluorine–18–Labeled Fluoromisonidazole Positron 
Emission and Computed Tomography–Guided Intensity–Modulated Radiotherapy for Head 
and Neck Cancer: A Feasibility Study. Int J Radiat Oncol Biol Phys 70(1): 2–13. 
Lee N, Nehmeh S, Schöder H, Fury M, Chan K, Ling CC, Humm J (2009) Prospective Trial 
Incorporating Pre–/Mid–Treatment [18F]–Misonidazole Positron Emission Tomography for 
Head–and–Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy. Int J Radiat 
Oncol Biol Phys 75(1): 101–8.  
Lee ST, Scott AM (2007) Hypoxia Positron Emission Tomography Imaging With 
18
F–
Fluoromisonidazole. Semin Nucl Med 37(6): 451–61. 
Lehtiö K, Oikonen V, Grönroos T, Eskola O, Kalliokoski K, Bergman J, Solin O, Grénman 
R, Nuutila P, Minn H (2001) Imaging of blood flow and hypoxia in head and neck cancer: 
Initial evaluation with [
15
O]H2O and [
18
F]Fluoroerythronitroimidazole PET. J Nucl Med 
42(11): 1643–52. 
Lehtiö K, Oikonen V, Nyman S, Grönroos T, Roivainen A, Eskola O, Minn H (2003) 
Quantifying tumour hypoxia with fluorine–18–fluoroerythronitroimidazole ([18F]FETNIM) 
and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging 30(1): 101–8.  
Lehtiö K, Eskola O, Viljanen T, Oikonen V, Grönroos T, Sillanmäki L, Grénman R, Minn H 
(2004). Imaging perfusion and hypoxia with PET to predict radiotherapy response in head–
and–neck cancer. Int J Radiat Oncol Biol Phys 59(4): 971–82. 
28 
 
Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA (2008) An imaging 
comparison of 64Cu–ATSM and 60Cu–ATSM in cancer of the uterine cervix. J Nucl Med 
49(7): 1177–82. 
Li L, Hu M, Zhu H, Zhao W, Yang G, Yu J (2010) Comparison of 
18
F–
fluoroerythronitroimidazole and 
18
F–fluorodeoxyglucose positron emission tomography and 
prognostic value in locally advanced non–small–cell lung cancer. Clin Lung Cancer 11(5): 
335–40. 
Lohith TG, Kudo T, Demura Y, Umeda Y, Kiyono Y, Fujibayashi Y, Okazawa H (2009) 
Pathophysiologic correlation between 
62
Cu–ATSM and 18F–FDG in lung cancer. J Nucl Med 
50(12): 1948–53. 
Matsumoto K, Szajek L, Krishna MC, Cook JA, Seidel J, Grimes K, Carson J, Sowers AL, 
English S, Green MV, Bacharach SL, Eckelman WC, Mitchell JB (2007) The influence of 
tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [
64
Cu]Cu-
ATSM or [
18
F]Fluoromisonidazole positron emission tomography. Int J Oncol 30(4): 873–81. 
McQuade P, Martin KE, Castle TC, Went MJ, Blower PJ, Welch MJ, Lewis JS (2005) 
Investigation into 
64
Cu–labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) 
complexes as hypoxia imaging agents. Nucl Med Biol 32(2): 147–56. 
Minagawa Y, Shizukuishi K, Koike I, Horiuchi C, Watanuki K, Hata M, Omura M, Odagiri 
K, Tohnai I, Inoue T, Tateishi U (2011) Assessment of tumor hypoxia by 
62
Cu–ATSM 
PET/CT as a predictor of response in head and neck cancer: A pilot study. Ann Nucl Med 
25(5): 339–45. 
29 
 
Mönnich D, Troost EGC, Kaanders JHAM, Oyen WJG, Alber M, Thorwarth D (2012) 
Modelling and simulation of the influence of acute and chronic hypoxia on 
[
18
F]fluoromisonidazole PET imaging. Phys Med Biol 57(6): 1675–84. 
Mortensen LS, Buus S, Nordsmark M, Bentzen L, Munk OL, Keiding S, Overgaard J (2010) 
Identifying hypoxia in human tumors: A correlation study between 
18
F–FMISO PET and the 
Eppendorf oxygen–sensitive electrode. Acta Oncol 49(7): 934–40. 
Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, Alsner J, Sørensen 
BS, Toustrup K, Jakobsen S, Petersen J, Petersen H, Theil J, Nordsmark M, Overgaard J 
(2012) FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head 
and neck treated with radiotherapy: Results from the DAHANCA 24 trial. Radiother Oncol 
105(1): 14–20. 
Nehmeh SA, Lee NY, Schröder H, Squire O, Zanzonico PB, Erdi YE, Greco C, Mageras G, 
Pham HS, Larson SM, Ling CC, Humm JL (2008) Reproducibility of Intratumor Distribution 
of 
18
F–Fluoromisonidazole in Head and Neck Cancer. Int J Radiat Oncol Biol Phys; 70(1): 
235–42.  
Nyflot MJ, Harari PM, Yip S, Perlman SB, Jeraj R (2012) Correlation of PET images of 
metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with 
cancer of the oropharynx. Radiother Oncol 105(1): 36–40.  
O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn 
RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL (2005) Assessment of 
regional tumor hypoxia using 
18
F–fluoromisonidazole and 64Cu(II)–diacetyl–bis(N4– 
methylthiosemicarbazone) positron emission tomography: Comparative study featuring 
30 
 
microPET imaging, pO2 probe measurement, autoradiography, and fluorescent microscopy in 
the R3327–AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 61(5): 1493–502. 
Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, Kuge Y, Shirato H, Tamaki N 
(2013) High reproducibility of tumor hypoxia evaluated by 
18
F– fluoromisonidazole pet for 
head and neck cancer. J Nucl Med 54(2): 201–7. 
Overgaard J (2011) Hypoxic modification of radiotherapy in squamous cell carcinoma of the 
head and neck – A systematic review and meta–analysis. Radiother Oncol 100(1): 22–32. 
Postema EJ, McEwan AJB, Riauka TA, Kumar P, Richmond DA, Abrams DN, Wiebe LI 
(2009) Initial results of hypoxia imaging using 1–α–d–(5–deoxy–5–[18F]–
fluoroarabinofuranosyl)–2–nitroimidazole (18F–FAZA). Eur J Nucl Med Mol Imaging 
36(10): 1565–73. 
Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, Chin LK, 
Hofstrand PD, Grierson JR, Eary JF, Krohn KA (2003) [
18
F]FMISO and [
18
F]FDG PET 
imaging in soft tissue sarcomas: Correlation of hypoxia, metabolism and VEGF expression. 
Eur J Nucl Med and Molecular Imaging 30(5): 695–704. 
Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence 
AM, Muzi M, Farwell DG, Krohn KA (2004) Hypoxia and Glucose Metabolism in Malignant 
Tumors: Evaluation by [
18
F]Fluoromisonidazole and [
18
F]]Fluorodeoxyglucose Positron 
Emission Tomography Imaging.  Clin Cancer Res 10(7): 2245–52. 
Rajendran JG, Schwartz DL, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J, Grierson JR, 
Krohn KA (2006) Tumor hypoxia imaging with [F–18] fluoromisonidazole positron emission 
tomography in head and neck cancer.  Clin Cancer Res 12(18): 5435–41. 
31 
 
Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, Krohn KA (1996) 
Quantifying regional hypoxia in human tumors with positron emission tomography of 
[
18
F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 
36(2): 417–28. 
Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, Peters LJ (2006) Prognostic 
significance of [
18
F]–misonidazole positron emission tomography–detected tumor hypoxia in 
patients with advanced head and neck cancer randomly assigned to chemoradiation with or 
without tirapazamine: A substudy of Trans–Tasman Radiation Oncology Group study 98.02. 
J Clin Oncol 24(13): 2098–104. 
Roels S, Slagmolen P, Nuyts J, Lee JA, Loeckx D, Maes F, Stroobants S, Penninckx F, 
Haustermans K (2008) Biological image–guided radiotherapy in rectal cancer: Is there a role 
for FMISO or FLT, next to FDG? Acta Oncol 47(7): 1237–48. 
Sato J, Kitagawa Y, Yamazaki Y, Hata H, Okamoto S, Shiga T, Shindoh M, Kuge Y, Tamaki 
N (2013) 
18
F–fluoromisonidazole PET uptake is correlated with hypoxia–inducible factor–1a 
expression in oral squamous cell carcinoma. J Nucl Med 54(7): 1060–5. 
Schuetz M, Schmid MP, Pötter R, Kommata S, Georg D, Lukic D, Dudczak R, Kletter K, 
Dimopoulos J, Karanikas G, Bachtiary B (2010) Evaluating repetitive 
18
F–fluoroazomycin–
arabinoside ( 
18
FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical 
cancer. Acta Oncol 49(7): 941–7. 
Segard T, Robins PD, Yusoff IF, Ee H, Morandeau L, Campbell EM, Francis RJ (2013) 
Detection of hypoxia with 
18
F–fluoromisonidazole (18F–FMISO) PET/CT in suspected or 
proven pancreatic cancer. Clin Nucl Med 38(1): 1–6. 
32 
 
Semenza GL (2004) Hydroxylation of HIF–1: Oxygen sensing at the molecular level. 
Physiology 19(4): 176–82.  
Shi K, Souvatzoglou M, Astner ST, Vaupel P, Nüsslin F, Wilkens JJ, Ziegler SI (2010) 
Quantitative assessment of hypoxia kinetic models by a cross–study of dynamic 18F–FAZA 
and 
15
O–H2O in patients with head and neck tumors. J Nucl Med 2010; 51(9): 1386–94. 
Shibahara I, Kumabe T, Kanamori M, Saito R, Sonoda Y, Watanabe M, Iwata R, Higano S, 
Takanami K, Takai Y, Tominaga T (2010) Imaging of hypoxic lesions in patients with 
gliomas by using positron emission tomography with 1–(2–[18F] fluoro–1–
[hydroxymethyl]ethoxy) methyl–2–nitroimidazole, a new 18F–labeled 2–nitroimidazole 
analog: Clinical article. J Neurosurg 113(2): 358–68. 
Souvatzoglou M,  rosu AL, R per  , Krause BJ, Beck R, Reischl G, Picchio M, Machulla 
HJ, Wester HJ, Piert M (2007) Tumour hypoxia imaging with [
18
F]FAZA PET in head and 
neck cancer patients: A pilot study. Eur J Nucl Med Mol Imaging 34(10): 1566–75. 
Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HL, Muzi M, Adamsen TC, 
Krohn KA, Spence AM (2009) Complementary but distinct roles for MRI and 
18
F–
fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med. 50(1): 36–
44.  
Takahashi N, Fujibayashi Y, Yonekura Y, Welch MJ, Waki A, Tsuchida T, Sadato N, 
Sugimoto K, Itoh H (2000) Evaluation of 
62
Cu labeled diacetyl–bis(N4–
methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl 
Med 14(5): 323–8. 
33 
 
Tateishi K, Tateishi U, Sato M, Yamanaka S, Kanno H, Murata H, Inoue T, Kawahara N 
(2013) Application of 
62
Cu–diacetyl–bis (N4– methylthiosemicarbazone) PET imaging to 
predict highly malignant tumor grades and hypoxia–inducible factor–1a expression in 
patients with glioma. Am J Neuroradiol 2013; 34(1): 92–9. 
Thorwarth D, Eschmann SM, Scheiderbauer J, Paulsen F, Alber M (2005) Kinetic analysis of 
dynamic 
18
F–fluoromisonidazole PET correlates with radiation treatment outcome in head–
and–neck cancer. BMC Cancer; 5: 152. 
Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M (2006) Combined uptake of 
[
18
F]FDG and [
18
F]FMISO correlates with radiation therapy outcome in head–and–neck 
cancer patients. Radiother Oncol 80(2): 151–6. 
Thureau S, Chaumet–Riffaud P, Modzelewski R, Fernandez P, Tessonnier L, Vervueren L, 
Cachin F, Berriolo-Riedinger A, Olivier P, Kolesnikov-Gauthier H, Blagosklonov O, Bridji 
B, Devillers A, Collombier L, Courbon F, Gremillet E, Houzard C, Caignon JM, Roux J, 
Aide N, Brenot-Rossi I, Doyeux K, Dubray B, Vera P (2013) Interobserver agreement of 
qualitative analysis and tumor delineation of 
18
F–fluoromisonidazole and 3'–deoxy–3'–18F–
fluorothymidine PET images in lung cancer. J Nucl Med 54(9): 1543–50. 
Trinkaus ME, Blum R, Rischin D, Callahan J, Bressel M, Segard T, Roselt P, Eu P, Binns D, 
MacManus MP, Ball D, Hicks RJ (2013) Imaging of hypoxia with 
18
F–FAZA PET in patients 
with locally advanced non–small cell lung cancer treated with definitive chemoradiotherapy. 
J Med Imaging Radiat Oncol 57(4): 475–81. 
Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF (1992) Hypoxia in human 
gliomas: Demonstration by PET with fluorine–18–fluoromisonidazole. J Nucl Med 1992; 
33(12): 2133–7. 
34 
 
Vaupel P, Harrison L (2004) Tumor hypoxia: Causative factors, compensatory mechanisms, 
and cellular response. Oncologist 9 (Suppl 5): 4–9.  
Vera P, Bohn P, Edet–Sanson A, Salles A, Hapdey S, Gardin I, Ménard JF, Modzelewski R, 
Thiberville L, Dubray B (2011) Simultaneous positron emission tomography (PET) 
assessment of metabolism with 
18
F–fluoro–2–deoxy–d–glucose (FDG), proliferation with 
18
F–fluoro–thymidine (FLT), and hypoxia with 18F–fluoro–misonidazole (F–miso) before and 
during radiotherapy in patients with non–small–cell lung cancer (NSCLC): A pilot study. 
Radiother Oncol 98(1): 109–16. 
Vercellino L, Groheux D, Thoury A, Delord M, Schlageter MH, Delpech Y, Barré E, Baruch-
Hennequin V, Tylski P, Homyrda L, Walker F, Barranger E, Hindié E (2012). Hypoxia 
imaging of uterine cervix carcinoma with 
18
F–FETNIM PET/CT. Clin Nucl Med 37(11): 
1065–8.  
Wang K, Yorke E, Nehmeh SA, Humm JL, Ling CC (2009) Modeling acute and chronic 
hypoxia using serial images of 
18
F–FMISO PET. Med Phys 2009; 36(10): 4400–8. 
Wilson WR, Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11(6): 
393–410. 
Yamane T, Kikuchi M, Shinohara S, Senda M (2011) Reduction of [
18
F]fluoromisonidazole 
uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma. Mol 
Imaging Biol 13(2): 227–31. 
Yue J, Yang Y, Cabrera AR, Sun X, Zhao S, Xie P, Zheng J, Ma L, Fu Z, Yu J (2012) 
Measuring tumor hypoxia with 
18
F–FETNIM PET in esophageal squamous cell carcinoma: a 
pilot clinical study. Dis Esophagus 25(1): 54–61. 
35 
 
Zegers CML, Van Elmpt W, Wierts R, Reymen B, Sharifi H, Öllers MC, Hoebers F, Troost 
EG, Wanders R, van Baardwijk A, Brans B, Eriksson J, Windhorst B, Mottaghy FM, De 
Ruysscher D, Lambin P (2013) Hypoxia imaging with [
18
F]HX4 PET in NSCLC patients: 
Defining optimal imaging parameters. Radiother Oncol 109(1): 58–64. 
Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M, Eble M, Buell U, 
Reinartz P (2006) FDG – A marker of tumour hypoxia? A comparison with [18F]–
fluoromisonidazole and pO2–polarography in metastatic head and neck cancer. Eur J Nucl 
Med Mol Imaging 33(12): 1426–31.  
  
36 
 
Table 1:  Characteristics of the ideal hypoxia tracer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pO2: partial oxygen pressure (mmHg) 
  
1 
Hypoxia-specific retained in regions with low pO2 levels, but not by normoxic or 
necrotic cells 
2 Mechanism of cellular retention should be well defined and cell type independent 
3 
Sufficiently lipophilic to enter cells and allow uniform tissue distribution, but also 
sufficiently hydrophilic to avoid membrane sequestration, and have faster clearance 
from systemic circulation and normoxic tissue. 
4 
Pharmacokinetic profile and tissue distribution should exhibit little dependence on 
parameters that may co-vary with hypoxia, such as blood flow or pH. 
5 High stability against non-hypoxia specific metabolism in vivo 
6 
Tissue kinetics should be suitable to imaging within a timeframe permitted in the 
clinical setting 
7 Should be easy to synthesize and readily available. 
8 Amenable dosimetry profile. 
9 Be repeatable to allow both detection of hypoxia and return to normoxia 
10 Should be effective in multiple tumour types. 
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Table 2: Clinical hypoxia studies with PET in tumours. 
Reference Tracer 
Tumour 
type(s) 
N 
Tracer retention 
(TBR; SUV) 
Results 
Valk et al 1992 18F–FMISO Brain 3 
T:P: 0·71–1·49 
at 120 min p.i. 
18F–FMISO–PET is a 
feasible method for 
detecting hypoxia in 
gliomas 
Bruehlmyer et al 2004 18F–FMISO Brain 11 
T:B: 0·96–2·07 
At 90 min & ≥170 
min p.i. 
Increased 18F–FMISO 
T:B observed in all 
tumours. T:B 
independent of tumour 
perfusion at later 
imaging times 
Cher et al 2006 18F–FMISO Brain 17 
– 
Static scan at 120 
min p.i. 
18F–FMISO uptake in 
high grade, but not low 
grade, gliomas. 
Correlation between 
18F–FDG or 18F–
FMISO uptake with 
Ki67 and VEGFR–1 
expression 
Swanson et al 2009 18F–FMISO Brain 24 
T:Bmax,pre–therapy:2·7 
T:Bmax,post–therapy:1·7 
Hypoxia volume 
generally straddled 
outer edge of the T1–
Gd abnormality. 
Correlation between 
hypoxic volume and 
T1–Gd 
abnormality.18F–
FMISO T:B reduced 
after therapy 
Cheng et al 2013 18F–FMISO Breast 20 
T:M2h,Baseline:  
0·72–3·07 
T:M4h,Baseline :  
0·8–2·29 
(16/20 patients) 
T:M2h,Follow–up: 0·27–
1·83 
T:M4h,Follow–up : 0·43–
2·28 
At 120 min & 180 
min p.i. 
Hypoxia thresholds: 
T:M>1·2; SUV≥2·1 
Correlation between 
FMISO uptake and 
endocrine therapy 
outcome. Poor 
correlation between 
FMISO uptake and 
HIF–1a 
immunostaining. 
Gagel et al 2004 18F–FMISO H&N 16 
T:M: 1·68 (range, 
1·23–2·28) 
Av SUVmean: 1·76; 
Av. SUVmax: 2·07 
At 120 min p.i. 
Average to high 
correlation between 
oxygen electrode and 
18F–FMISO T:M and 
SUV. No correlation 
between tumour 
oxygenation status and 
18F–FDG uptake 
Hicks et al 2005 18F–FMISO H&N 15 
SUVmax 
Tumour: 2·5±0·5 
Nodes: 2·3±0·5 
At 120 min p.i. 
Positive 18F–FMISO 
uptake in 13 patients. 
Qualitative decrease in 
18F–FMISO and 18F–
FDG uptake induced by 
therapy 
Thorwarth et al 2005 18F–FMISO H&N 15 
Median SUVmax: 
2·25 
(range, 1·36–4·04) 
at 120 min & 180 
min p.i. 
Different types of 
characteristic hypoxia–
perfusion patterns 
identified in tumours 
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Rajendran et al 2006 18F–FMISO H&N 73 
Mean 
T:Bmax1·6±0·46 
T:B and presence of 
nodes were strong 
independent predictors 
of survival 
Richin et al 2006  18F–FMISO H&N 45 
Independent hypoxic 
score 
Static scan at 120 
min p.i. 
Higher risk of 
locoregional failure in 
hypoxic tumours. 
Patients on 
tirapazamine had lower 
risk of locoregional 
failure 
Thorwarth et al 2006 18F–FMISO H&N 12 
SUVmax: 2·20 (range, 
1·4–3·22) 
At 120 min and 240 
min p.i 
Hypoxia definition: 
SUV>1·4 
No correlation between 
18F–FDG and 18F–
FMISO SUV. 
Maximum 18F–FMISO 
SUV showed borderline 
significance for 
stratifying patient group 
Zimny et al 2006 18F–FMISO H&N 24 
Normoxic 
T:Mmean1·4 
Hypoxic T:Mmean: 
1·8 
18F–FMISO T:M higher 
in hypoxic tumours (as 
detected with oxygen 
electrode).Moderate 
correlation between 
18F–FDG and 18F–
FMISO uptake. 
Eschmann et al 2007 18F–FMISO H&N 14 
SUVmean, pre–therapy 
2·54±0·81 
T:M pre–therapy 
1·9±0·64 
SUVmean, post–therapy : 
1·98±0·47, 
T:M post–therapy : 
1·49±0·26 
At 240 min p.i. 
Hypoxia definition: 
T:M≥2 threshold 
Radiotherapy 
decreased18F–FMISO 
SUV and T:M ratio. 
Gagel et al 2007 18F–FMISO H&N 38 
SUVmean: 1·69 
SUVmax: 1·98 
T:Mmean: 1·57 
T:Bmean: 1·13 
Moderate correlation 
between oxygen 
measurements and 18F–
FMISO uptake. Low 
correlation between 
18F–FDG and 18F–
FMISO 
Lee et al 2008 18F–FMISO H&N 20 
Static scan at 120–
150 min p.i. 
Hypoxia definition: 
T:M≥1·3 
Variable 18F–FMISO 
distribution 
Nehmeh et al 2008 18F–FMISO H&N 13 
SUV 1·9–4·5 
At 117–195 p.i. 
T R≥1·2 
Good correlations intra–
tumour18F–FMISO 
distributions in 6/13 
patients, consistent with 
chronic hypoxia 
Dirix et al 2009 18F–FMISO H&N 15 
Hypoxic volumepre–
therapy 4·1ml, 
T:Bmax, pre–therapy : 1·5 
Hypoxic volume post–
therapy : 0·3ml 
T:Bmax,post–therapy: 1·2 
at 120–160 min p.i 
Hypoxia definition: 
T:B>1·2 
Disease free survival 
correlates negatively 
with baseline T:Bmax 
and initial hypoxic 
volume 
Lee et al 2009 18F–FMISO H&N 28 – 
Heterogeneous 
distribution of 18F–
FMISO noted in the 
primary and/or nodal 
disease in 90% of 
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patients 
Abolmaali et al 2011 18F–FMISO H&N 23 
SUVmax,2h: 2·2 
(range,1·3–3·4) 
T:M2h: 1·46 
SUVmax,4h: 2·4 
(range,1·1–4·4) 
T:M4h: 1·6 
18F–FMISO contrast 
increases 2h–4h p.i. 
Kikuchi et al 2011 18F–FMISO H&N 17 
Median SUVmax: 2·3 
Median T:M: 1·3 
At 150 min p.i. 
Hypoxia definition: 
1·3 
Disease specific 
survival was 
significantly lower in 
patient group with high 
basal 18F–FMISO 
SUVmax and T:Mmax 
Yamane et al 2011 18F–FMISO H&N 13 
SUVmax,pre–therapy2·2 
(range, 0·7–3·6) 
T:M,pre–therapy : 1·6 
(range: 1·1–2·2). 
Responders: 
–18·7% SUVmax; 
–22·5% T:M; 
–82·65% hypoxic 
volume Non–
responders: 
–5·5% SUVmax 
10·2% T:M 
–8·8% hypoxic 
volume 
(–/+ denote % 
increase and decrease 
respectively) 
At 150 min p.i. 
18F–FMISO SUVmax, 
T:M and hypoxic 
volume significantly 
decreased after neo-
adjuvant chemotherapy 
Sato et al 2013 18F–FMISO H&N 23 
Median SUVmax: 1·83 
(range, 0·8–2·7) 
Median SUVmax: 16·5 
(range, 1·0–32·3) 
Weak significant 
correlation between 
18F–FMISO and 18F–
FDG SUVmax. 
18F–
FMISO SUVmax was 
significantly higher in 
HIF–1α–positive cases 
than in HIF–1α–
negative cases. 
Okamoto et al 2013 18F–FMISO H&N 11 
SUVmax,Baseline:3·16±
1·29 
SUVmax,48h : 
3·02±1·12 
T:BBaseline: 2·98±0·83 
T:B48h: 2·97 ± 0·64 
T:MBaseline : 2·25 ± 
0·71 
T:M48h : 2·19 ± 0·67 
At 240 min p.i. 
Hypoxia threshold: 
T: ≥1·5; T:M≥1·25 
High reproducibility 
between SUV, T:B, 
T:M and hypoxic 
volume measurements 
between the two 18F–
FMISO scans 
(baseline and at 48h) 
Mortensen et al 2010 18F–FMISO 
H&N 
Sarcoma 
19 
T:Mmed: 
H&N: 1·68 
(range, 0·7–2·38) 
Sarcoma: 0·78 
(range, 0·7–1) 
No correlation between 
18F–FMISO retention 
and oxygen electrode 
Koh et al 1995 18F–FMISO Lung 7 
Static scan at 120–
180p.i. 
T R≥1·4 threshold 
to define hypoxia 
Radiotherapy reduced 
median fractional 
hypoxic volume from 
58% to 22% 
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Cherk et al 2006 18F–FMISO Lung 21 
SUV: 0·4–2·14; 
T:N: 1·18–9·73 
At 120 min p.i. 
Low 18F–FMISO 
uptake. Poor correlation 
between 18F–FMISO 
and 18F–FDG uptake 
Gagel et al 2006 18F–FMISO Lung 8 
SUVmean, pre–therapy: 
2·31 ± 0·2 
SUVmax, pre–therapy: 
2·77 ±0·27 
T:Mpre–therapy: 
1·99±0·49 
SUVmean, post–therapy: 
1·83 ± 0·12 
SUVmax, post–
therapy:2·19±0·13 
T:Mpost–therapy : 
1·36±0·08 
At 180 min p.i. 
18F–FMISO can define 
hypoxic sub–regions. 
Changes in FMISO and 
18F–FDG PET measure 
early response to 
therapy. 
Vera et al 2011 
(22) 
18F–FMISO Lung 5 
SUVmax, pre–therapy : 1–
2·5 
SUVmax, post–therapy: 1–
2·4 
18F–FMISO uptake 
higher in tumours than 
nodes and did not 
change during therapy 
Thureau et al 2013 18F–FMISO Lung 10 – 
Low reproducibility and 
inter–observer 
agreement for 18F–
FMISO volume 
measurements on the 
basis of visual scoring. 
T:M≥1·4 recommended 
for hypoxic volume 
delineation. 
Segard et al 2013 18F–FMISO Pancreatic 10 
Mean SUVmax: 2·3 
(range, 1–3·4) 
18F–FMISO 
accumulation observed 
in 2/10 patients on the 
basis of visual analysis. 
Minimal 18F–FMISO 
accumulation in 
pancreatic tumours; 
correlation with other 
imaging modalities 
required to allow 
tumour localization and 
semi–quantitative 
analysis. 
Hugonet et al 2011 18F–FMISO Renal 53 
Static scan at 120 
min p.i. 
Hypoxia definition: 
TBR>1·2 
Reduction in hypoxic 
volume post–therapy. 
Roels et al 2008 18F–FMISO Rectal 15  
Mismatch between 18F–
FDG and 18F–FMISO 
scans.18F–FMISO 
uptake reduced after 
therapy 
Bentzen et al 2003 18F–FMISO Sarcoma 13 T:M <1–1·6 
18F–FMISO 
accumulation observed 
in 2/7 malignant 
tumours. 
No correlation between 
18F–FMISO and pO2 
measurements 
Rajendran et al 2003 18F–FMISO Sarcoma 19 
T:Bmax1·10–3·46 
At 120 min p.i. 
T R≥1·2 to define 
hypoxia 
18F–FMISO uptake 
observed in 14 patients. 
Poor correlation 
between tumour grade, 
hypoxia volume and 
18F–FDG T:B. 
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Rajendran et al 2004 18F–FMISO 
Brain 
Breast 
H&N 
Sarcoma 
49 
T:Bmax: 
Brain 2·43 
(range, 1·7–2·9) 
Breast 1·52 
(range, 0·93–2·6) 
H&N: 1·5 
(range, 0·88–2·4) 
Sarcoma: 1·46 
(range, 1·1–2·1) 
Hypoxia detected in all 
tumour types. Low 
correlation between 
glucose metabolism and 
hypoxia 
Schuetz et al 2010 18F–FAZA Cervical 15 
T:Mmax: 1·2–3·6 
At 60 min & 120 min 
p.i. 
5/15 patients had 
visually identifiable 
tumours. 
Grosu et al 2007 18F–FAZA H&N 18 
T:Mmean: 1·6 
T:Mmax: 2 
At 120 min p.i. 
Hypoxia threshold: 
SUV≥1·5 
18F–FAZA uptake 
located in single 
confluent region in 
11/18 patients and as 
multiple diffuse regions 
in 4/18 patients 
Souvatzoglou et al 2007 18F–FAZA H&N 11 
SUVmax: 2·3 
(range, 1·5–3·4) 
SUVmean: 1·4 
(range, 1–2·1) 
T:M: 2 
(range, 1·6–2·4) 
T:M ratio increased 
60min post injection. ll 
tumours had T:M>1·5· 
Tumour volume with 
T:M>1·5 was highly 
variable 
Mourtensen et al 2011 18F–FAZA H&N 40 
Median T:Mmax1·5 
At 120 min p.i. 
Hypoxia threshold: ≥ 
1·4 
High uptake associated 
with lower disease–free 
survival. Radiotherapy 
treatment reduced 
hypoxic volume 
Bollineni et al 2013 18F–FAZA Lung 11 
Median T:B : 2·8 
(range, 1·8–4·6) 
T: ≥1·2 for hypoxic 
volume definition. 
Not significant 
correlation between 
18F–FAZA T:B and 
18F–FDG SUVmax or 
lesion size. 
Heterogeneous intra–
tumoural distribution 
for 18F–FAZA based 
visual analysis.18F–
FAZA PET is able to 
detect heterogeneous 
distributions of hypoxic 
sub–volumes. 
Trinkhaus et al 2013 18F–FAZA Lung 17 – 
11/17 patients had 
baseline hypoxia based 
on qualitative 
assessment. 6/8 patients 
with scans following 
chemoradiation had 
resolution of hypoxia on 
the basis of qualitative 
analysis. 
Garcia–Parra et al 2011 18F–FAZA Prostate 14 T:Nmean : 1·21 
18F–FAZA uptake not 
increased in tumours. 
No evidence of hypoxia 
as assessed by CaIX 
IHC staining 
Havelund et al 2013 18F–FAZA Rectal 14 T:Mmean : 2·83 
18F–FAZA–PET is 
feasible for 
visualization of hypoxia 
in rectal cancer. 
Postema et al 2009 18F–FAZA 
H&N 
Lung 
Lymphoma 
Glioma 
50 
H&N TBR : 1·2–2·7; 
SUVmax1·05–2·35 
Lung TBR : 1·3–3·7; 
SUVmax0·81–1·93 
Lymphoma TBR: 
1·2–3; SUVmax1·07–
High TBR in all 7 
gliomas; high TBR, 
SUVmax observed in 6/9 
H&N tumours; 
moderate TBR, SUVmax 
in 3/21 lymphomas; 
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4·52 
Glioma TBR : 1·9–
15·6 
At 120–180 min p.i. 
increased TBR, 
SUVmaxin 7/11 lung 
patients 
Lethiö et al 2001 18F–FETNIM H&N 8 T:Mmax 1–4 at 3h p.i. 
Tumour distribution 
volume correlated 
strongly with 18F–
FETNIM SUV between 
60 and 120 min p.i. and 
blood flow, but not with 
18F–FDG SUV. Values 
compare favourably 
with 18F–FMISO data. 
Late time–point 18F–
FETNIM T:M are 
indicative of hypoxia. 
Lethiö et al 2003 18F–FETNIM H&N 10 
Median T:M: 1·41 
(range, 0·86–2) 
Median T:Pmean: 0·96 
(range, 0·74–1·1) 
Median T:Pmax: 1·29 
(range, 0·91–1·98) 
T:P is good estimate of 
tumour hypoxia 
Lethiö et al 2004 18F–FETNIM H&N 21 
Median T:Pmax : 1·10 
(range, 0·81–1·98) 
T:P>0·93 used for 
hypoxic volume 
definition 
Patients with higher 
fractional hypoxic 
volumes and T:P 
correlated with poorer 
survival. 
Hu et al 2010 18F–FETNIM Lung 42 
SUVmax,Tumour: 2·43 
SUVmax,Normal: 0·87 
T:N: 2·48 
at 120 min p.i. 
SUVmax higher in 
tumours than normal 
tissue. Similar data 
observed at 60 and 120 
min p.i. 
Li et al 2010 18F–FETNIM Lung 26 – 
18F–FETNIM T:B ratio 
and hypoxic volume 
were strong predictors 
for overall survival. No 
correlation between 
18F–FETNIM and18F– 
FDG uptake 
Vercellino et al 2012 18F–FETNIM Cervical 16 T:M : 1·3–5·4 
High uptake associated 
with lower progression 
free and overall survival 
Yue et al 2012 18F–FETNIM Oesophageal 28 
SUVmax, complete response: 
3·2 
SUVmean, complete 
response : 2·1 
SUVmax, partial response: 
4·5 
SUVmean, partial response: 
2·9 
SUVmax, stable disease: 
5·9 
SUVmean, stable disease: 
3·2 
Threshold for 
hypoxia 
SUVmax:SUVmean,splee
n: 1·3 
SUVmax, SUVmean are 
reproducible. High 
baseline SUVmax 
associated with poor 
clinical response 
Zegers et al 2013 18F–HX4 Lung 15 
SUVmax,2h : 1·47 ± 
0·36 
SUVmax,4h : 1·34 ± 
0·37 
T:Bmax,2h : 1·56 ± 
0·30 
T:Bmax,2h : 2·03 ± 
0·55 
T:Bmax>1·4 at 240 min 
p.i. was observed in 
80% of the primary 
tumours and 60% of 
lymph node regions. 
T:Bmax increased over 
acquisition time, 
although pattern 
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at 240 min p.i 
Hypoxia threshold: 
T:B>1·4 
stabilized between 120–
180 min p.i. 
Kaneta 2007 18F–FRP170 
Normal 
Lung 
4/3 
T:M1h : 1·69 
T:B1h : 1·09 
T:M2h : 1·96 
T:B2h : 1·24 
at 120 min p.i. 
T:B stable at 60–120 
min p.i. Images 
obtained 60 min p.i. 
may allow evaluation of 
tumour accumulation in 
a clinical setting 
Shibahara et al 2010 18F–FRP170 Brain 8 SUVmax : 1·3–2·3 
SUVmax correlated 
positively with HIF–1a 
immunostaining. 
Beppu et al 2013 18F–FRP170 Brain 12 
SUVmean, Tumour : 
1·58±0·35 
SUVmean, Normal : 
0·82±0·16 
T:N : 1·95±0·33 
Significant correlation 
between T:N, pO2, and 
strong nuclear 
immunostaining for 
HIF–1α in areas of high 
18F–FRP170 
accumulation 60 min p.i 
in glioblastoma patients. 
Dehdashti et al 2004 60Cu–ATSM Cervical 14 Mean T:M 3·4±2·8 
Tumour uptake of 60Cu–
ATSM inversely related 
to progression–free 
survival and overall 
survival. No correlation 
between FDG and 
60Cu–ATSM uptake 
Grigsby et al 2007 60Cu–ATSM Cervical 15 – 
4 year overall survival 
estimates were 75% for 
patients with non–
hypoxic tumours and 
33% for those with 
hypoxic tumours. 
Overexpression of 
VEGF, EGFR, COX2, 
CAIX and increased 
apoptosis observed in 
hypoxic tumours. 
Dehdashti et al 2008 60Cu–ATSM Cervical 38 T:M 3·8±2·0 
Tumour uptake of 60Cu–
ATSM was inversely 
related to progression–
free survival and cause–
specific survival. 3 year 
progression free 
survival of patients with 
non–hypoxic tumours 
was 71%, and 28% for 
those with hypoxic 
tumours 
Minagawa et al 2011 62Cu–ATSM H&N 15 
Mean 
SUVmax5·5±1·7 
All 5 patients with 
SUVmax<5 were 
complete responders 
Dehdashti et al 2003 60Cu–ATSM Lung 19 
Mean T:Mpre–
therapy2·3±1 
Mean SUVmean, pre–
therapy:3·2±1 
Responders: 
Mean T:M pre–therapy: 
1·5 
Non–responders: 
Mean T:M pre–therapy: 
3·4 
Imaging with 60Cu–
ATSM feasible in 
NSCLC. Mean T:M 
lower in responders 
than non–responders. 
Mean SUV not different 
between these groups 
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Dietz et al 2008 60Cu–ATSM Rectal 19 
Mean T:M 2·5±0·9 
At 30–60 min p.i. 
Hypoxia threshold: 
T:M>2·6 
Median tumour–to–
muscle activity ratio of 
2·6 discriminated those 
with worse prognosis 
from those with better 
prognosis. Overall and 
progression–free 
survival worse in 
hypoxic tumours 
Lolith et al 2009 62Cu–ATSM Lung 13 
SUVmean, SCC: 
1·95±0·88 
SUVmean, Adenocarcinoma 
: 1·54±0·92 
At 30 min & 60 min 
p.i. 
18F–FDG and 62Cu–
ATSM had spatially 
similar distributions in 
adenocarcinomas 
Note: N= number of patients; T:M: tumour–to–muscle ratio; T:P: tumour–to–plasma ratio; T:B: tumour–to blood ratio; T:N: 
tumour–to–normal–tissue ratio; TBR: tumour–to–background ratio; SUV: standardized uptake value; pO2: partial oxygen 
pressure; p.i.:post injection; VEGFR: vascular endothelial growth factor; EGFR: epidermal growth factor; CAIX: carbonic 
anhydrase IX; H&N: head and neck cancer, NSCLC: non–small cell lung cancer; RT: radiotherapy 
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Tumor type 18F-FMISO 18F-HX4 18F-FAZA 18F-FETNIM 18F-EF5 18F-FRP170 Cu-ATSM 
Brain Yes Not recommended Yes 
 
Recommended Yes Recommended 
Head & Neck Yes Yes Yes Yes Yes  Yes 
Breast Yes 
    
 
 
Sarcoma Variable data 
    
 
 
Lung Yes Yes Yes Yes 
 
Yes Yes 
Lymphoma 
  
Yes 
  
 
 
Renal 
Variable data 
Not recommended 
Not recommended Not recommended Not recommended Not recommended  Recommended 
Liver Not recommended Recommended 
 
Not recommended Not recommended  Not recommended 
Colorectal 
No 
Not recommended  
Yes Not recommended Not recommended  Yes 
Bladder Not recommended Not recommended Not recommended Not recommended Not recommended  Recommended 
Cervical 
  
Yes Yes 
 
 Yes 
Prostate 
  
No 
  
 Not recommended 
Table 3: Matrix summarising clinical imaging findings with leading hypoxia tracers 
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Titles and legends to figures 
Figure 1: Structures and logP values of PET hypoxia radiotracers. The logP value (partition 
coefficient) of each radiotracer is shown in the parentheses. Positive logP values indicate a 
lipophilic molecule, whereas negative logP values represent a hydrophilic molecule. 
Figure 2:  Tumour-to-reference-tissue ratios and range in different tumour sites for the PET 
hypoxia tracers discussed in this review. For nitroimidazole-based analogues (FMISO, 
FAZA, FETNIM, HX4, FRP-170) values are given for acquisitions performed at 120 min 
post tracer administration. For Cu-ATSM values are presented for scans conducted 60 min. 
Figure 3: (a) Transverse 
18
F-FMISO fused PET/CT overlay image acquired at baseline of a 
patient with metastatic renal cell carcinoma (mRCC) in the neck acquired at 2.5-3h p.i (image 
courtesy of Professors Tim Eisen and Duncan Jodrell, University of Cambridge, UK) (b) 
64
Cu-ATSM fused PET/CT overlay image of a patient with advanced laryngeal squamous cell 
carcinoma (LSCC) at 80-90 min p.i. The transverse slice includes primary tumour and local 
lymph node (image courtesy of Dr Anastasia Chalkidou, King’s College London, UK) 
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